Biocon Foundation constructs new high school building in Karnataka
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The facility has been designed with a dual focus on efficiency and sustainability
        Subscribe To Our Newsletter & Stay Updated